Article

CRISPR Screens Identify Essential Cell Growth Mediators in BRAF-inhibitor Resistant Melanoma

2019-12-17

Abstract excerpt

BRAF is a serine-threonine kinase that harbors activating mutations in ∼7% of human malignancies and ∼60% of melanomas. Despite initial clinical responses to BRAF inhibitors (BRAFi), patients frequently develop drug resistance. To identify candidate therapeutic targets for BRAFi-resistant melanoma, we conducted CRISPR screens in melanoma cells harboring an activating BRAF mutation that had also acquired resistance...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a5709834-76bc-536c-8143-56f77f1ed918
DOI: 10.1101/2019.12.16.876631

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

CRISPR Screens Identify Essential Cell Growth Mediators in BRAF-inhibitor Resistant MelanomaDOI 10.1101/2019.12.16.876631Read

CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma.Semantic proximity Read

Identification of pathways modulating Vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screenSemantic proximity Read

Identification of pathways modulating vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screen.Semantic proximity Read

Landscape of enhancer disruption and functional screen in melanoma cells.Semantic proximity Read

Identification of BRAF Inhibitor Resistance-associated lncRNAs Using Genome-scale CRISPR-Cas9 Transcriptional Activation Screening.Semantic proximity Read

Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1RSemantic proximity Read

Specific <i>SOX10</i> enhancer elements modulate phenotype plasticity and drug resistance in melanomaSemantic proximity Read

Mutation-Specific CRISPR Targeting with SaCas9 and AsCas12a Restores Therapeutic Sensitivity in Treatment-Resistant Melanoma.Semantic proximity Read

Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma.Semantic proximity Read

Transposon mediated functional genomic screening for BRAF inhibitor resistance reveals convergent Hippo and MAPK pathway activation eventsSemantic proximity Read

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma.Semantic proximity Read

Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAFV600E/NRASQ61K Melanoma Enhancing Tumor Growth and Metastasis in a Bioluminescent Murine Model.Semantic proximity Read